Gene engineering as envisioned by science fiction isn't coming. It's already here. How can you cash in? Small-cap biotech Intellia Therapeutics (NSDQ: NTLA) is by far the best way to profitably leverage the accelerating trend of creating new drugs by editing genes. Today's heroes of innovation are the biologists, chemists, and other scientists who are forging novel medicines from gene-editing "toolkits." This is the new frontier of science. Biotech firms are editing DNA to treat and prevent diseases such as Alzheimer's, Huntington's, Parkinson's, multiple sclerosis, sickle cell anemia, a wide range of cancers… just about any ailment you can think of. |
没有评论:
发表评论